Safety and Quality of life (QOL): secondary end point
toxicities, neutropenia
ADVERSE EVENTS, NEUTROPENIA
Grade 3-4 treatment-related adverse events occurred in 60.6% and 57.5% of patients in the RP and P groups, respectively. Frequent grade 3-4 toxicities in the RP and P groups were neutropenia (11% Major treatment-based adverse eventsRP, raltitrexed plus paclitaxel; P, paclitaxel.